Women's Health Reports (Nov 2022)
Minimal Stimulation Using Gonadotropin-Releasing Hormone Antagonist is Associated with Higher Live Birth Rates: A National Study of 13,050 Cycles
Abstract
Background: The optimal protocol for minimal stimulation in vitro fertilization (IVF) has yet to be established. This study aims to determine if the use of gonadotropin-releasing hormone (GnRH) antagonist during minimal stimulation improves outcomes. Materials and Methods: All cycles designated as minimal stimulation from 2014 to 2016 from the Society for Assisted Reproductive Technology Clinic Online Reporting System were identified. Cycles in which GnRH antagonist was administered (n?=?5984) were compared to those that did not receive it (n?=?7066). Wilcoxon's rank-sum test and chi-square test were used to analyze continuous and categorical variables. Results: A total of 6750 patients undergoing 13,050 cycles were included. GnRH antagonist use was associated with a significantly higher total gonadotropin dosage (median 975.0 [interquartile range, IQR, 600.0, 1575.0] vs. median 660.0 [IQR 375.0, 975.0], p?<?0.001), lower cycle cancelation rate (11.3% vs. 13.6%, p?<?0.001; OR 1.24, 95% CI 1.12?1.38, p?<?0.001), and higher live birth rate (4.3% vs. 2.1%, p?<?0.001; OR 0.47, 95% CI 0.39?0.58, p?<?0.001). GnRH antagonist use was associated with a significantly higher live birth rate in women ?35 years of age (2.7% vs. 0.9%, p?<?0.001; OR 0.34, 95% CI 0.25?0.47, p?<?0.001) and antimullerian hormone <1 (4.9% vs. 2.6%, p?=?0.004; OR 0.52, 95% CI 0.33?0.81, p?=?0.004). Conclusion: The use of GnRH antagonist suppression during minimal stimulation IVF is associated with an improved live birth rate, especially in older women and in women with diminished ovarian reserve. Although GnRH antagonist use may increase costs, it significantly decreases cancelation rate, increases number of embryos cryopreserved, and should be encouraged for minimal stimulation IVF.
Keywords
